Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia
August 09, 2023 07:05 ET
|
Virios Therapeutics
ATLANTA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
August 03, 2023 16:05 ET
|
Virios Therapeutics
ATLANTA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral...
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study
July 17, 2023 07:05 ET
|
Virios Therapeutics
ATLANTA, July 17, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia
July 11, 2023 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expansion of its sales force to drive further adoption of Quell® Fibromyalgia, which is the first...
Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia
May 15, 2023 07:05 ET
|
Virios Therapeutics
ATLANTA, May 15, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Therapeutics Announces First Quarter 2023 Financial Results
May 11, 2023 07:05 ET
|
Virios Therapeutics
ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Aviv Clinics Highlights New Hyperbaric Oxygen Therapy Study Bringing Hope to Fibromyalgia Patients
March 21, 2023 11:06 ET
|
Aviv Clinics
ORLANDO, Fla., March 21, 2023 (GLOBE NEWSWIRE) -- Aviv Clinics, one of the most advanced brain research and medical clinics in the world, today is sharing the results of a new study that shows...
NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting
March 21, 2023 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in...
Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
March 14, 2023 07:05 ET
|
Virios Therapeutics
ATLANTA, March 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
Anticonvulsant Drugs Market to Surpass US$ 8,030.4 Million by 2030, Says Coherent Market Insights (CMI)
February 22, 2023 09:15 ET
|
CMI
Burlingame, Feb. 22, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global anticonvulsant drugs market is estimated to be valued at US$ 6,757.8 in 2022 and is expected to...